For combination therapy, the most potent DOT1L inhibitor EPZ5676 showed synergy with daunorubicin and cytarabine, two standard agents in current chemotherapy for AML [153, 154]; an EZH2 inhibitor EPZ6438 (tazemetostat), in combination with prednisolone, entered phase II clinical trials for diffuse large B-cell lymphoma (Trial number: NCT01897571). The gene discussed is DOT1L; the disease is acute myeloid leukemia.